ID   ANDR_RAT                Reviewed;         902 AA.
AC   P15207; Q63049;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-OCT-2024, entry version 224.
DE   RecName: Full=Androgen receptor;
DE   AltName: Full=Dihydrotestosterone receptor;
DE   AltName: Full=Nuclear receptor subfamily 3 group C member 4;
GN   Name=Ar; Synonyms=Nr3c4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3216867; DOI=10.1210/mend-2-12-1276;
RA   Tan J., Joseph D.R., Quarmby V.E., Lubahn D.B., Sar M., French F.S.,
RA   Wilson E.M.;
RT   "The rat androgen receptor: primary structure, autoregulation of its
RT   messenger ribonucleic acid, and immunocytochemical localization of the
RT   receptor protein.";
RL   Mol. Endocrinol. 2:1276-1285(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Prostate;
RX   PubMed=3174628; DOI=10.1073/pnas.85.19.7211;
RA   Chang C., Kokontis J., Liao S.;
RT   "Structural analysis of complementary DNA and amino acid sequences of human
RT   and rat androgen receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7211-7215(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TFM GLN-735.
RX   PubMed=2341409; DOI=10.1016/s0021-9258(19)38972-0;
RA   Yarbrough W.G., Quarmby V.E., Simental J.A., Joseph D.R., Sar M.,
RA   Lubahn D.B., Olsen K.L., French F.S., Wilson E.M.;
RT   "A single base mutation in the androgen receptor gene causes androgen
RT   insensitivity in the testicular feminized rat.";
RL   J. Biol. Chem. 265:8893-8900(1990).
RN   [4]
RP   INTERACTION WITH HIPK3, AND SUBCELLULAR LOCATION.
RC   TISSUE=Testis;
RX   PubMed=9725910; DOI=10.1091/mbc.9.9.2527;
RA   Moilanen A.-M., Karvonen U., Poukka H., Jaenne O.A., Palvimo J.J.;
RT   "Activation of androgen receptor function by a novel nuclear protein
RT   kinase.";
RL   Mol. Biol. Cell 9:2527-2543(1998).
RN   [5]
RP   INTERACTION WITH SRA1.
RX   PubMed=12350225; DOI=10.1042/bj20020743;
RA   Kawashima H., Takano H., Sugita S., Takahara Y., Sugimura K., Nakatani T.;
RT   "A novel steroid receptor co-activator protein (SRAP) as an alternative
RT   form of steroid receptor RNA-activator gene: expression in prostate cancer
RT   cells and enhancement of androgen receptor activity.";
RL   Biochem. J. 369:163-171(2003).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-290 AND SER-633, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 647-902 OF MUTANT ALA-860 IN
RP   COMPLEX WITH DIHYDROTESTOSTERONE.
RX   PubMed=11320241; DOI=10.1073/pnas.081565498;
RA   Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y.,
RA   Scheffler J.E., Salvati M.E., Krystek S.R. Jr., Weinmann R., Einspahr H.M.;
RT   "Crystallographic structures of the ligand-binding domains of the androgen
RT   receptor and its T877A mutant complexed with the natural agonist
RT   dihydrotestosterone.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:4904-4909(2001).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 533-637 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND SUBUNIT.
RX   PubMed=15037741; DOI=10.1073/pnas.0401123101;
RA   Shaffer P.L., Jivan A., Dollins D.E., Claessens F., Gewirth D.T.;
RT   "Structural basis of androgen receptor binding to selective androgen
RT   response elements.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4758-4763(2004).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 647-902 OF MUTANT ALA-860 IN
RP   COMPLEX WITH SYNTHETIC ANTAGONIST.
RX   PubMed=15603938; DOI=10.1016/j.bmcl.2004.10.085;
RA   Salvati M.E., Balog A., Shan W., Wei D.D., Pickering D., Attar R.M.,
RA   Geng J., Rizzo C.A., Gottardis M.M., Weinmann R., Krystek S.R., Sack J.,
RA   An Y., Kish K.;
RT   "Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-
RT   dione based androgen receptor antagonists.";
RL   Bioorg. Med. Chem. Lett. 15:271-276(2005).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 647-902 IN COMPLEX WITH SYNTHETIC
RP   ANDROGEN ANTAGONIST, AND FUNCTION.
RX   PubMed=17181141; DOI=10.1021/jm061101w;
RA   Sun C., Robl J.A., Wang T.C., Huang Y., Kuhns J.E., Lupisella J.A.,
RA   Beehler B.C., Golla R., Sleph P.G., Seethala R., Fura A., Krystek S.R. Jr.,
RA   An Y., Malley M.F., Sack J.S., Salvati M.E., Grover G.J., Ostrowski J.,
RA   Hamann L.G.;
RT   "Discovery of potent, orally-active, and muscle-selective androgen receptor
RT   modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.";
RL   J. Med. Chem. 49:7596-7599(2006).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 647-902 IN COMPLEX WITH THE
RP   SYNTHETIC AGONIST MBS-564929, AND FUNCTION.
RX   PubMed=17008401; DOI=10.1210/en.2006-0843;
RA   Ostrowski J., Kuhns J.E., Lupisella J.A., Manfredi M.C., Beehler B.C.,
RA   Krystek S.R. Jr., Bi Y., Sun C., Seethala R., Golla R., Sleph P.G.,
RA   Fura A., An Y., Kish K.F., Sack J.S., Mookhtiar K.A., Grover G.J.,
RA   Hamann L.G.;
RT   "Pharmacological and X-ray structural characterization of a novel selective
RT   androgen receptor modulator: potent hyperanabolic stimulation of skeletal
RT   muscle with hypostimulation of prostate in rats.";
RL   Endocrinology 148:4-12(2007).
CC   -!- FUNCTION: Steroid hormone receptors are ligand-activated transcription
CC       factors that regulate eukaryotic gene expression and affect cellular
CC       proliferation and differentiation in target tissues. Transcription
CC       factor activity is modulated by bound coactivator and corepressor
CC       proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen
CC       response elements/ARE on target genes, negatively regulating androgen
CC       receptor signaling and androgen-induced cell proliferation.
CC       Transcription activation is also down-regulated by NR0B2. Activated,
CC       but not phosphorylated, by HIPK3 and ZIPK/DAPK3 (By similarity).
CC       {ECO:0000250|UniProtKB:P10275, ECO:0000269|PubMed:17008401,
CC       ECO:0000269|PubMed:17181141}.
CC   -!- SUBUNIT: Binds DNA as a homodimer. Part of a ternary complex containing
CC       AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the
CC       presence of androgen. The ligand binding domain interacts with
CC       KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with
CC       EFCAB6/DJBP, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1, ZNF318 and
CC       RREB1. Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance
CC       its transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4.
CC       Interacts with MACROD1 (via macro domain) (By similarity). Interacts
CC       via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1,
CC       NCOA2, NCOA3 and MAGEA11. Interacts (via nuclear receptor DNA binding
CC       domain and nuclear receptor ligand binding domain) with NCOA4 (By
CC       similarity). The AR N-terminal poly-Gln region binds Ran resulting in
CC       enhancement of AR-mediated transactivation. Ran-binding decreases as
CC       the poly-Gln length increases. Interacts with HIP1 (via coiled coil
CC       domain). Interacts (via ligand-binding domain) with TRIM68. Interacts
CC       with TNK2. Interacts with USP26. Interacts with RNF6. Interacts
CC       (regulated by RNF6 probably through polyubiquitination) with RNF14;
CC       regulates AR transcriptional activity. Interacts with PRMT2 and TRIM24.
CC       Interacts with RACK1. Interacts with RANBP10; this interaction enhances
CC       dihydrotestosterone-induced AR transcriptional activity. Interacts with
CC       PRPF6 in a hormone-independent way; this interaction enhances
CC       dihydrotestosterone-induced AR transcriptional activity. Interacts with
CC       STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with LPXN. Interacts
CC       with MAK. Part of a complex containing AR, MAK and NCOA3. Interacts
CC       with CRY1. Interacts with CCAR1 and GATA2 (By similarity). Interacts
CC       with BUD31 (By similarity). Interacts with ARID4A (By similarity).
CC       Interacts with ARID4B (By similarity). Interacts (via NR LBD domain)
CC       with ZBTB7A; the interaction is direct and androgen-dependent (By
CC       similarity). Interacts with NCOR1 (By similarity). Interacts with NCOR2
CC       (By similarity). Interacts with CRY2 in a ligand-dependent manner (By
CC       similarity). {ECO:0000250|UniProtKB:P10275,
CC       ECO:0000250|UniProtKB:P19091, ECO:0000269|PubMed:11320241,
CC       ECO:0000269|PubMed:12350225, ECO:0000269|PubMed:15037741,
CC       ECO:0000269|PubMed:15603938, ECO:0000269|PubMed:17008401,
CC       ECO:0000269|PubMed:17181141, ECO:0000269|PubMed:9725910}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9725910}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P10275}. Note=Detected at the promoter of target
CC       genes. Predominantly cytoplasmic in unligated form but translocates to
CC       the nucleus upon ligand-binding. Can also translocate to the nucleus in
CC       unligated form in the presence of RACK1.
CC       {ECO:0000250|UniProtKB:P10275}.
CC   -!- TISSUE SPECIFICITY: Highest levels in the seminal vesicle, ventral
CC       prostate and coagulating gland with lower levels in the kidney and
CC       levator ani muscle.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC       DNA-binding domain and a C-terminal ligand-binding domain. In the
CC       presence of bound steroid the ligand-binding domain interacts with the
CC       N-terminal modulating domain, and thereby activates AR transcription
CC       factor activity. Agonist binding is required for dimerization and
CC       binding to target DNA. The transcription factor activity of the complex
CC       formed by ligand-activated AR and DNA is modulated by interactions with
CC       coactivator and corepressor proteins. Interaction with RANBP9 is
CC       mediated by both the N-terminal domain and the DNA-binding domain.
CC       Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated in prostate cancer cells in response to several
CC       growth factors including EGF. Phosphorylation is induced by c-Src
CC       kinase (CSK). Tyr-517 is one of the major phosphorylation sites and an
CC       increase in phosphorylation and Src kinase activity is associated with
CC       prostate cancer progression (By similarity). Phosphorylation by TNK2
CC       enhances the DNA-binding and transcriptional activity. Phosphorylation
CC       at Ser-61 by CDK9 regulates AR promoter selectivity and cell growth.
CC       Phosphorylation by PAK6 leads to AR-mediated transcription inhibition
CC       (By similarity). {ECO:0000250|UniProtKB:P10275}.
CC   -!- PTM: Sumoylated on Lys-384 (major) and Lys-503 (By similarity).
CC       Ubiquitinated. Deubiquitinated by USP26 (By similarity). 'Lys-6' and
CC       'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional
CC       activity and specificity (By similarity).
CC       {ECO:0000250|UniProtKB:P10275}.
CC   -!- PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required
CC       for plasma membrane targeting and for rapid intracellular signaling via
CC       ERK and AKT kinases and cAMP generation (By similarity).
CC       {ECO:0000250|UniProtKB:P10275}.
CC   -!- DISEASE: Note=Defects in Ar are a cause of androgen insensitivity. Rats
CC       with this syndrome are called testicular feminized (TFM).
CC       {ECO:0000269|PubMed:2341409}.
CC   -!- MISCELLANEOUS: In the absence of ligand, steroid hormone receptors are
CC       thought to be weakly associated with nuclear components; hormone
CC       binding greatly increases receptor affinity. The hormone-receptor
CC       complex appears to recognize discrete DNA sequences upstream of
CC       transcriptional start sites.
CC   -!- MISCELLANEOUS: Transcriptional activity is enhanced by binding to
CC       RANBP9.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M20133; AAA40733.1; -; mRNA.
DR   EMBL; M23264; AAA40759.1; -; mRNA.
DR   EMBL; J05454; AAA40734.1; -; Genomic_DNA.
DR   PIR; B40494; B40494.
DR   RefSeq; NP_036634.1; NM_012502.1.
DR   PDB; 1I37; X-ray; 2.00 A; A=647-902.
DR   PDB; 1I38; X-ray; 2.00 A; A=647-902.
DR   PDB; 1R4I; X-ray; 3.10 A; A/B=533-637.
DR   PDB; 1XNN; X-ray; 2.20 A; A=647-902.
DR   PDB; 2IHQ; X-ray; 2.00 A; A=647-902.
DR   PDB; 2NW4; X-ray; 3.00 A; A=647-902.
DR   PDB; 3G0W; X-ray; 1.95 A; A=647-902.
DR   PDB; 7ZTV; X-ray; 1.94 A; A=654-902.
DR   PDBsum; 1I37; -.
DR   PDBsum; 1I38; -.
DR   PDBsum; 1R4I; -.
DR   PDBsum; 1XNN; -.
DR   PDBsum; 2IHQ; -.
DR   PDBsum; 2NW4; -.
DR   PDBsum; 3G0W; -.
DR   PDBsum; 7ZTV; -.
DR   AlphaFoldDB; P15207; -.
DR   SMR; P15207; -.
DR   BioGRID; 246396; 4.
DR   DIP; DIP-5963N; -.
DR   IntAct; P15207; 1.
DR   STRING; 10116.ENSRNOP00000009129; -.
DR   BindingDB; P15207; -.
DR   ChEMBL; CHEMBL3072; -.
DR   DrugCentral; P15207; -.
DR   GuidetoPHARMACOLOGY; 628; -.
DR   iPTMnet; P15207; -.
DR   PhosphoSitePlus; P15207; -.
DR   PaxDb; 10116-ENSRNOP00000009129; -.
DR   GeneID; 24208; -.
DR   KEGG; rno:24208; -.
DR   AGR; RGD:2147; -.
DR   CTD; 367; -.
DR   RGD; 2147; Ar.
DR   eggNOG; KOG3575; Eukaryota.
DR   InParanoid; P15207; -.
DR   OrthoDB; 5351241at2759; -.
DR   PhylomeDB; P15207; -.
DR   TreeFam; TF350286; -.
DR   Reactome; R-RNO-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand.
DR   Reactome; R-RNO-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-RNO-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-RNO-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   EvolutionaryTrace; P15207; -.
DR   PRO; PR:P15207; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016607; C:nuclear speck; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0005497; F:androgen binding; IMP:RGD.
DR   GO; GO:0051117; F:ATPase binding; ISO:RGD.
DR   GO; GO:0008013; F:beta-catenin binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:RGD.
DR   GO; GO:0003677; F:DNA binding; TAS:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0034056; F:estrogen response element binding; IBA:GO_Central.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISO:RGD.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IPI:RGD.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:RGD.
DR   GO; GO:0070974; F:POU domain binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0032553; F:ribonucleotide binding; IDA:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0001223; F:transcription coactivator binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0060520; P:activation of prostate induction by androgen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IMP:RGD.
DR   GO; GO:0048645; P:animal organ formation; ISO:RGD.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; ISO:RGD.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEP:RGD.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IEP:RGD.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; ISO:RGD.
DR   GO; GO:0007620; P:copulation; IMP:RGD.
DR   GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; ISO:RGD.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; ISO:RGD.
DR   GO; GO:0050673; P:epithelial cell proliferation; ISO:RGD.
DR   GO; GO:0030520; P:estrogen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0009566; P:fertilization; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060599; P:lateral sprouting involved in mammary gland duct morphogenesis; ISO:RGD.
DR   GO; GO:0033327; P:Leydig cell differentiation; ISO:RGD.
DR   GO; GO:0008049; P:male courtship behavior; IMP:RGD.
DR   GO; GO:0048808; P:male genitalia morphogenesis; ISO:RGD.
DR   GO; GO:0008584; P:male gonad development; ISO:RGD.
DR   GO; GO:0046661; P:male sex differentiation; IMP:RGD.
DR   GO; GO:0019102; P:male somatic sex determination; ISO:RGD.
DR   GO; GO:0060749; P:mammary gland alveolus development; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; ISO:RGD.
DR   GO; GO:0060571; P:morphogenesis of an epithelial fold; ISO:RGD.
DR   GO; GO:0035264; P:multicellular organism growth; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:RGD.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISO:RGD.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045720; P:negative regulation of integrin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0140694; P:non-membrane-bounded organelle assembly; ISO:RGD.
DR   GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; IBA:GO_Central.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; ISO:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:RGD.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0045726; P:positive regulation of integrin biosynthetic process; ISO:RGD.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0060406; P:positive regulation of penile erection; IMP:RGD.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; ISO:RGD.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; ISO:RGD.
DR   GO; GO:0060736; P:prostate gland growth; IEP:RGD.
DR   GO; GO:0048638; P:regulation of developmental growth; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0060685; P:regulation of prostatic bud formation; ISO:RGD.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; ISS:UniProtKB.
DR   GO; GO:0003073; P:regulation of systemic arterial blood pressure; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0019098; P:reproductive behavior; IDA:RGD.
DR   GO; GO:0048608; P:reproductive structure development; ISO:RGD.
DR   GO; GO:0061458; P:reproductive system development; ISO:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0072520; P:seminiferous tubule development; ISO:RGD.
DR   GO; GO:0007338; P:single fertilization; ISO:RGD.
DR   GO; GO:0014734; P:skeletal muscle hypertrophy; IMP:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IMP:RGD.
DR   GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; ISO:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd07173; NR_DBD_AR; 1.
DR   CDD; cd07073; NR_LBD_AR; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1.
DR   Gene3D; 1.10.565.10; Retinoid X Receptor; 1.
DR   InterPro; IPR001103; Andrgn_rcpt.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR050200; Nuclear_hormone_rcpt_NR3.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR48092:SF13; ANDROGEN RECEPTOR; 1.
DR   PANTHER; PTHR48092; KNIRPS-RELATED PROTEIN-RELATED; 1.
DR   Pfam; PF02166; Androgen_recep; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00521; ANDROGENR.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1.
DR   SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Disease variant; DNA-binding; Isopeptide bond;
KW   Lipid-binding; Lipoprotein; Metal-binding; Nucleus; Palmitate;
KW   Phosphoprotein; Receptor; Reference proteome; Steroid-binding;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..902
FT                   /note="Androgen receptor"
FT                   /id="PRO_0000053712"
FT   DOMAIN          651..882
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        541..614
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         542..562
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         578..602
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..569
FT                   /note="Interaction with ZNF318"
FT                   /evidence="ECO:0000250|UniProtKB:P19091"
FT   REGION          1..540
FT                   /note="Modulating"
FT   REGION          35..146
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          194..224
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          439..465
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          534..901
FT                   /note="Interaction with LPXN"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   REGION          554..644
FT                   /note="Interaction with HIPK3"
FT                   /evidence="ECO:0000269|PubMed:9725910"
FT   REGION          574..901
FT                   /note="Interaction with CCAR1"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   REGION          607..901
FT                   /note="Interaction with KAT7"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   COMPBIAS        59..74
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        89..105
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         688
FT                   /ligand="17beta-hydroxy-5alpha-androstan-3-one"
FT                   /ligand_id="ChEBI:CHEBI:16330"
FT                   /evidence="ECO:0000269|PubMed:11320241,
FT                   ECO:0007744|PDB:1I37"
FT   BINDING         735
FT                   /ligand="17beta-hydroxy-5alpha-androstan-3-one"
FT                   /ligand_id="ChEBI:CHEBI:16330"
FT                   /evidence="ECO:0000269|PubMed:11320241,
FT                   ECO:0007744|PDB:1I37"
FT   BINDING         860
FT                   /ligand="17beta-hydroxy-5alpha-androstan-3-one"
FT                   /ligand_id="ChEBI:CHEBI:16330"
FT                   /evidence="ECO:0000269|PubMed:11320241,
FT                   ECO:0007744|PDB:1I37"
FT   SITE            703
FT                   /note="Interaction with coactivator LXXL and FXXFY motifs"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   SITE            880
FT                   /note="Interaction with coactivator FXXLF and FXXFY motifs"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         61
FT                   /note="Phosphoserine; by CDK9"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         75
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         221
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         265
FT                   /note="Phosphotyrosine; by CSK and TNK2"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         290
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         305
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         344
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         355
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         360
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         361
FT                   /note="Phosphotyrosine; by CSK and TNK2"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         391
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         517
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         534
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   MOD_RES         633
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         898
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   CROSSLNK        384
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        503
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        828
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   CROSSLNK        830
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P10275"
FT   VARIANT         735
FT                   /note="R -> Q (in TFM; has only 10-15% of the androgen-
FT                   binding capacity of wild-type AR)"
FT                   /evidence="ECO:0000269|PubMed:2341409"
FT   CONFLICT        195
FT                   /note="Missing (in Ref. 3; AAA40734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        389
FT                   /note="S -> L (in Ref. 2; AAA40759)"
FT                   /evidence="ECO:0000305"
FT   STRAND          543..545
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   STRAND          551..553
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   STRAND          556..558
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   HELIX           560..570
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   STRAND          579..582
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   TURN            588..593
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   HELIX           595..605
FT                   /evidence="ECO:0007829|PDB:1R4I"
FT   HELIX           655..663
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          674..676
FT                   /evidence="ECO:0007829|PDB:1I37"
FT   HELIX           680..703
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           708..710
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           713..739
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          745..748
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          751..753
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           755..760
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           764..779
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           784..795
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          797..800
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           807..826
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          827..829
FT                   /evidence="ECO:0007829|PDB:2IHQ"
FT   TURN            832..834
FT                   /evidence="ECO:0007829|PDB:2NW4"
FT   HELIX           835..865
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   TURN            866..871
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           876..884
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   HELIX           886..890
FT                   /evidence="ECO:0007829|PDB:7ZTV"
FT   STRAND          893..896
FT                   /evidence="ECO:0007829|PDB:7ZTV"
SQ   SEQUENCE   902 AA;  98218 MW;  43F4064759FDCBED CRC64;
     MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REAIQNPGPR HPEAASIAPP GACLQQRQET
     SPRRRRRQQH PEDGSPQAHI RGTTGYLALE EEQQPSQQQS ASEGHPESGC LPEPGAATAP
     GKGLPQQPPA PPDQDDSAAP STLSLLGPTF PGLSSCSADI KDILSEAGTM QLLQQQQQQQ
     QQQQQQQQQQ QQQQQEVISE GSSSVRAREA TGAPSSSKDS YLGGNSTISD SAKELCKAVS
     VSMGLGVEAL EHLSPGEQLR GDCMYASLLG GPPAVRPTPC APLAECKGLS LDEGPGKGTE
     ETAEYSSFKG GYAKGLEGES LGCSGSSEAG SSGTLEIPSS LSLYKSGAVD EAAAYQNRDY
     YNFPLALSGP PHPPPPTHPH ARIKLENPSD YGSAWAAAAA QCRYGDLASL HGGSVAGPST
     GSPPATASSS WHTLFTAEEG QLYGPGGGGG SSSPSDAGPV APYGYTRPPQ GLASQEGDFS
     ASEVWYPGGV VNRVPYPSPS CVKSEMGPWM ENYSGPYGDM RLDSTRDHVL PIDYYFPPQK
     TCLICGDEAS GCHYGALTCG SCKVFFKRAA EGKQKYLCAS RNDCTIDKFR RKNCPSCRLR
     KCYEAGMTLG ARKLKKLGNL KLQEEGENSS AGSPTEDPSQ KMTVSHIEGY ECQPIFLNVL
     EAIEPGVVCA GHDNNQPDSF AALLSSLNEL GERQLVHVVK WAKALPGFRN LHVDDQMAVI
     QYSWMGLMVF AMGWRSFTNV NSRMLYFAPD LVFNEYRMHK SRMYSQCVRM RHLSQEFGWL
     QITPQEFLCM KALLLFSIIP VDGLKNQKFF DELRMNYIKE LDRIIACKRK NPTSCSRRFY
     QLTKLLDSVQ PIARELHQFT FDLLIKSHMV SVDFPEMMAE IISVQVPKIL SGKVKPIYFH
     TQ
//
